|Day's Range||366.50 - 376.00|
|52 Week Range||197.00 - 376.00|
|PE Ratio (TTM)||374.50|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Q4 2016 Bavarian Nordic A/S Earnings Call
The world should be far better prepared for the next Ebola outbreak, with further promising results on Tuesday showing the potential of a long-lasting vaccine against the deadly virus. The two-part shot from Johnson & Johnson and Danish partner Bavarian Nordic induced a durable immune response lasting a full year in 100 percent of healthy volunteers vaccinated, researchers reported. "The persistence of vaccine-induced immunity to one year post-immunisation is truly impressive," said researcher Matthew Snape of the University of Oxford.
Q2 2016 Bavarian Nordic A/S Earnings Call